Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6GWAC)

Drug Name
DDATHF Drug Info
Synonyms
DATHF; 95693-76-8; 5,10-dideazatetrahydrofolate; 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid; 5,10-dideazatetrahydrofolic acid; L-Glutamic acid,N-[4-[2-(2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]-; L-Glutamic acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-; C21H25N5O6; AC1L2XXH; Pyrido(2,3-d)pyrimidine, L-glutamic acid deriv; CHEMBL142806; SCHEMBL9045915; ZUQBAQVRAURMCL-CVRLYYSRSA-N; 5,10-Dideazatetrahydrofolic Acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
135436405
TTD Drug ID
DM6GWAC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting GAR transformylase (GART)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AG2034 DMFU58V Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Drug(s) Targeting Polypeptide deformylase (PDF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Proguanil DMBL79I Malaria 1F40-1F45 Approved [4]
Meprobamate DMHM93Y Anxiety Approved [5]
Pralatrexate DMAO80I Breast cancer 2C60-2C65 Approved [6]
Ustekinumab DMHTYK3 Plaque psoriasis EA90.0 Approved [7]
Trimetrexate DMDEA85 Toxoplasmosis 1F57 Approved [8]
MCB-3837 DM0R4Z5 Malaria 1F40-1F45 Approved [5]
Chlorproguanil DM1IFGT Malaria 1F40-1F45 Approved [5]
LY333531 DMGMC8H Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
Metoprine DM5GQD7 Advanced cancer 2A00-2F9Z Phase 2 [10]
Aminopterin DMQ9RBV leukaemia 2A60-2B33 Withdrawn from market [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GAR transformylase (GART) TTCSJBZ PUR2_HUMAN Modulator [2]
Polypeptide deformylase (PDF) TT9SL3Q DEFM_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,... Biochemistry. 2003 May 27;42(20):6043-56.
3 Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7.
4 Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
5 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
8 Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
9 Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
10 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
11 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.